Emerging health concerns in the United States may be quietly contributing to a surge in cancer cases among its population.

A comprehensive analysis involving over 50 million adults has revealed that metabolic syndrome—a combination of conditions such as high blood pressure, elevated blood sugar, excess abdominal fat, and high cholesterol—significantly increases the likelihood of developing various cancers linked to obesity. Moreover, it severely diminishes the chances of surviving colorectal cancer.

Researchers from the University of Utah and the Huntsman Cancer Institute conducted an extensive review of 21 systematic reviews and meta-analyses, encompassing nearly 100 studies, to reach these conclusions.

The findings strongly suggest a connection between metabolic syndrome and colorectal and kidney cancers, while a suggestive link was noted for breast and endometrial cancers. The term ‘highly suggestive’ indicates robust statistical support for these associations, making them unlikely to be coincidental. Additionally, noteworthy links were identified for pancreatic, liver, and esophageal cancers.

Individuals with metabolic syndrome were found to have a 41% higher chance of developing colorectal cancer and a 67% increased risk for kidney cancer. The syndrome also correlated with a 27% greater risk of breast cancer, a 49% higher risk of endometrial cancer, and a 33% increased risk of pancreatic cancer.

Interestingly, the study highlighted that the presence of more metabolic abnormalities correlated with a greater overall cancer risk and worse survival outcomes for colorectal cancer. These results persisted even when controlling for body weight, indicating that metabolic dysfunction itself, beyond obesity, plays a crucial role in cancer development.

Obesity-related cancers account for about four in 10 cancer diagnoses in the US. This umbrella review found that metabolic syndrome drives up the risk of several of these cancers, including colorectal, breast, endometrial, kidney, liver, pancreatic and esophageal cancers, even after accounting for obesity. 

The elevated risk persisted in normal-weight individuals with metabolic dysfunction, meaning the cluster of conditions itself drives cancer risk, not just excess body weight alone. 

Obesity-related cancers now account for nearly 40 percent of all US cancer diagnoses. And people with at least three metabolic syndrome components face a 30 percent higher risk of developing them (stock)

The study authors said: ‘Although there is variability in study quality, the consistency and strength of these associations, particularly for colorectal cancer, highlight the importance of addressing metabolic syndrome as a key modifiable risk factor in cancer development and progression.’

In the new study published in the journal Obesity Reviews, weaker yet still statistically significant links were seen for liver cancer, with a 74 percent higher risk and esophageal adenocarcinoma, the most common form of esophageal cancer, with a 21 percent higher risk.

Ovarian and thyroid cancers showed positive associations but did not reach statistical significance, largely due to the limited number of studies.

Sex differences emerged as well. Men with metabolic syndrome had a 38 percent higher risk of colorectal cancer and a 41 percent higher risk of liver cancer.

Women faced a 35 percent higher risk of colorectal cancer and a 58 percent higher risk of pancreatic cancer, the latter classified as weak evidence due to a smaller number of cases.

There are several theories to explain the sex difference, but a leading one points to estrogen. The hormone appears to exert a protective effect against the chronic, low-grade inflammation that links metabolic dysfunction to cancer, particularly in the colon, where estrogen helps dampen the damaging cellular changes driven by poor metabolic health. 

Without this brake, men may be more vulnerable to the carcinogenic effects of conditions like high blood sugar, excess belly fat and abnormal cholesterol. 

Confirming the dose-dependent relationship, meaning the more metabolic abnormalities a person has, the worse their outcome, the analysis found that people with two components of metabolic syndrome faced 2.6 times poorer colorectal cancer survival. Twith three or more components faced 4.5 times poorer survival. 

Scientists are still piecing together exactly how metabolic syndrome fuels cancer, but several key mechanisms have emerged.

Chronic inflammation is often central to cancer research. A silent, long-term threat, chronic inflammation revs up the immune system, which then attacks healthy cells and tissues. Even at low levels, years spent in a systemic, inflamed state can lead to chronic fatigue and pain.

Visceral fat around the organs, producing what some would refer to as an apple body shape, actively produces inflammatory chemicals that can damage DNA and signal cells to divide more frequently than they should. 

At the same time, metabolic syndrome throws hormones out of balance. It dampens the production of adiponectin, a hormone that normally helps protect against inflammation and uncontrolled cell growth.

It also drives up insulin resistance, forcing the pancreas to pump out more and more insulin. High insulin levels, in turn, can act as a growth fuel for certain cancer cells.

Over time, this environment becomes fertile ground for tumors to take root, grow and spread.

Colorectal cancer is increasingly becoming a blight in young, otherwise healthy people’s lives, striking those as young as their early 20s. About 20 percent of CRC diagnoses are now made in people under 55, a sharp contrast from the traditional older population of patients. 

Since the 1990s, colorectal cancer rates among adults under 50 have nearly doubled, with cases in the 20-to-39 age group climbing steadily by two percent each year. The disease is now one of the deadliest cancers for younger adults. 

More than 40 percent of Americans are obese, according to federal data. The prevalence of severe obesity was 9.4 percent

James Van Der Beek died at 48 from colorectal cancer. Healthy and with no family history, he dismissed a bowel habit change as coffee. A colonoscopy revealed stage 3 cancer. He urged others not to ignore the signs

Meanwhile, pancreatic cancer, long considered a disease of older adults, is quietly rising in younger Americans. 

The condition typically strikes people over 65, particularly those with long-standing risk factors like smoking, obesity or type 2 diabetes. Each year, about 67,000 Americans are diagnosed and more than 52,000 die from it. 

But a 2025 analysis shows that between 2000 and 2021, diagnoses jumped 4.3 percent annually among 15- to 34-year-olds and 1.5 percent annually among those age 35 to 54. The absolute numbers are small, but specialists say the trend is deeply concerning. 

James Van Der Beek, best known for his role in Dawson’s Creek, died Wednesday at age 48 from colorectal cancer. He was fit, healthy and had no family history of cancer when he noticed a subtle change in his bowel habits. 

He initially dismissed it, attributing it to his morning coffee. But when symptoms persisted, he underwent a colonoscopy and was diagnosed with stage 3 colorectal cancer in November 2024 at age 47, placing him in the category of early-onset cases diagnosed before 50. 

Despite treatment, the cancer was aggressive. Insiders said he eventually stopped treatment after doctors had nothing more to offer. Van Der Beek spent his final years urging others not to ignore the signs he almost missed. 

Metabolic syndrome can be reversed through adherence to a healthy diet – doctors and nutritionists favor the anti-inflammatory Mediterranean diet – as well as physical exercise, weight loss, stress management and the complete cessation of smoking. 

This study has limitations. The underlying research it analyzed was often low-quality, with inconsistent definitions of metabolic syndrome and wide variation between studies. Because the data comes from observational research, it can show strong links but cannot prove that metabolic syndrome directly causes cancer. And while the evidence for cancer risk is solid, data on survival after diagnosis is still thin.